Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation
Condition(s):Plasma Cell LeukemiaLast Updated:September 23, 2021Not yet recruiting
Include Studies Not Open or Pending
Condition(s):Plasma Cell LeukemiaLast Updated:September 23, 2021Not yet recruiting
Condition(s):Plasma Cell LeukemiaLast Updated:February 20, 2024Recruiting
Condition(s):Plasma Cell LeukemiaLast Updated:August 8, 2023Recruiting
Condition(s):Multiple Myeloma; Plasma Cell LeukemiaLast Updated:April 20, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple Myeloma; Plasma Cell LeukemiaLast Updated:October 24, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple Myeloma; Plasma Cell LeukemiaLast Updated:May 24, 2022Recruiting
Condition(s):Relapsed and/or Refractory Multiple Myeloma; Plasma Cell Leukemia in RelapseLast Updated:June 8, 2023Recruiting
Condition(s):Multiple Myeloma; Primary Plasma Cell LeukemiaLast Updated:December 1, 2023Recruiting
Condition(s):Multiple Myeloma; Plasma Cell LeukemiaLast Updated:September 21, 2023Recruiting
Condition(s):Multiple Myeloma; Primary Plasma Cell LeukemiaLast Updated:March 27, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.